Evidence map›Paper›PMID 42851375›Full record

ArticleFrontiers in oncology2026

Case Report: Discordance between RNA-identified

Shogen Boku, Takao Fujisawa, Tomofumi Sakagami, Shigenori Kadowaki, Hironaga Satake, Hisateru Yasui, Koushiro Ohtsubo, Yasushi Shimizu, Tomoyuki Otsuka, Bunya Kuze and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shogen BokuDepartment of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan.
Takao FujisawaDepartment of the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Tomofumi SakagamiDepartment of Otorhinolaryngology, Head and Neck Surgery, Kansai Medical University, Hirakata, Japan.
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Hisateru YasuiDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Koushiro OhtsuboDepartment of Medical Oncology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Tomoyuki OtsukaDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Bunya KuzeDepartment of Head and Neck Surgery, Central Japan International Medical Center, Minokamo, Gifu, Japan.
Riu YamashitaDepartment of the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Taro ShibukiDepartment of the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Yoshiaki NakamuraDepartment of the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Hideaki BandoDepartment of the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Takayuki YoshinoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Milan RadovichCaris Life Sciences, Phoenix, AZ, United States.
Masao YagiDepartment of Otorhinolaryngology, Head and Neck Surgery, Kansai Medical University, Hirakata, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory carcinoma of the salivary gland is a rare, fusion-driven malignancy in which kinase fusions can serve as therapeutic targets. We report a patient with an

Indexed as

case reportcomprehensive genomic profilingDNA profilingETV6::RETRNA sequencingsalivary gland secretory carcinoma

Identifiers

PMID42851375
PMCPMC13645586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.